Refine by
Lung Cancer Articles & Analysis
263 news found
Yang, L., et al (2024) introduces LungVis 1.0, an AI-driven imaging platform integrating light sheet fluorescence microscopy (LSFM) and deep learning for mapping nanoparticle (NP) deposition across murine lungs. The research highlights the advantages of aerosol-based delivery methods over traditional liquid-based approaches, emphasizing the uniformity of NP deposition in distal alveolar ...
In the United States, the Centers for Disease Control and Prevention (CDC) reports that more men and women die in this country from lung cancer than from any other type of cancer. This correlates to approximately 136,000 annual deaths and just under 200,000 people that are told they have lung cancer each year. ...
In this piece, we talked to the two presenters of the poster “The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS”, Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. The poster was recently presented at the ESMO ...
The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy. ...
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to ...
ByTempus
The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer recurrence and monitor for immunotherapy treatment response, providing valuable insights to inform patient management strategies. ...
ByTempus
Bayer is progressing novel research around its prostate cancer treatment darolutamide. The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models. Darolutamide, which is jointly developed by Bayer and ...
ByBayer AG
Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. ...
We are delighted and extremely grateful to have this financial support to expand our global R&D collaboration with leading institutions that are evaluating BioMark’s early lung cancer detection assay as we are rapidly proceeding into commercialization phase in North ...
With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. Representative data of the liquid biopsy workflow will be presented at the American Association for Cancer Research (AACR) Annual Meeting ...
The lung cancer screening demonstration project led by Dr Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Québec-Université Laval – IUCPQ-UL) is intended to combine BioMark’s metabolomics liquid biopsy test with radiomics and genetics biomarkers ...
Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and ...
While DNA is largely identical in all cells, RNA fluctuates considerably both in presence and relative concentrations. The variation reflects the underlying cause of a cell’s character and thus RNA analysis gives a more accurate view of the state cells are in compared to DNA analysis. Gene expression levels are important to analyse, and quantitative RNA sequencing is the most informative ...
Business Update Highlights “Our Q2 results demonstrate BioMark’s continued efforts to advance our technology platform with exceptional clinical data, expand our global partnerships, and accelerating the commercialization of its early lung cancer blood-based assay despite a challenging macro environment” said CEO Rashid Bux. ...
(NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022. ...
Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients ...
The isotope will be used by in combination with Radiopharm's propriety nanobody in a Phase I therapeutic dose escalation trial in patients with non-small cell lung cancer. The trial is planned to start in Ql 2023 in collaboration with GenesisCare and ANSTO. ...
“The 52.4% ORR from the TORCH-2 study with ATG-008 and toripalimab in patients with relapsed/metastatic cervical cancer, coupled with a manageable safety profile, is an exciting result that provides a potential guide to a registration program for ATG-008. ...
” Endometrioid Endometrial Cancer and the Upcoming Phase 1/2a Trial Endometrial cancer (EC) arises in the uterine lining and is the most common cancer of the female reproductive organs. ...
Meshinchi is Professor, Clinical Research Division, at Fred Hutchinson Cancer Research Center and Professor, Division of Pediatric Hematology-Oncology, at the University of Washington School of Medicine. ...